Your browser doesn't support javascript.
loading
Effect of miR-196a inhibition on esophageal cancer growth in vitro.
Bai, Minghua; Dong, Yiping; Zhou, Congya; Sun, Xiao; Ma, Jinlu; Han, Suxia.
Affiliation
  • Bai M; Department of Oncology, the 1st Affiliated Hospital, Xi'an Jiaotong University.
  • Dong Y; Department of Oncology, the 2nd Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
  • Zhou C; Department of Oncology, the 1st Affiliated Hospital, Xi'an Jiaotong University.
  • Sun X; Department of Oncology, the 1st Affiliated Hospital, Xi'an Jiaotong University.
  • Ma J; Department of Oncology, the 1st Affiliated Hospital, Xi'an Jiaotong University.
  • Han S; Department of Oncology, the 1st Affiliated Hospital, Xi'an Jiaotong University.
Anticancer Drugs ; 31(2): 169-176, 2020 02.
Article in En | MEDLINE | ID: mdl-31743132
ABSTRACT
Esophageal cancer has recent shown a higher incidence but lower 5-year survival rate after normal clinical treatment in China. The aim of this study was to observe whether the inhibition of miR-196a affects esophageal cancer cell growth by modulating the nuclear factor-κB target gene and to detect the possible cooperative therapeutic effects on esophageal cancer by knocking down miR-196a expression combined with the specific inhibitor of nuclear factor-κB target genes. Thus, anti-miR-196a or sotrastaurin, a protein kinase C (PKC) inhibitor, were used to alter PKC expression. We found that miR-196a knockdown or PKC inhibition by sotrastaurin changed PKC expression which then reduced esophageal cancer cell proliferation and downregulated proliferating cell nuclear antigen expression via the classical B-cell receptor-PKC nuclear factor-κB pathway but not the alternative pathway; in addition, miR-196a inhibition can increase the caspase level and induce esophageal cancer cell apoptosis. Our current results provided the evidence that miR-196a was related to the classical nuclear factor-κB pathway, and these new findings proved the potential therapeutic effect of miR-196a in targeted therapy for clinical esophageal cancer patients.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Biomarkers, Tumor / Gene Expression Regulation, Neoplastic / MicroRNAs Limits: Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Esophageal Neoplasms / Biomarkers, Tumor / Gene Expression Regulation, Neoplastic / MicroRNAs Limits: Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2020 Document type: Article